Oncor regulatory update

The FDA has asked ONC to re-run certain previously examined specimens at an independent laboratory and to co-develop a physician education/training program to help ensure the reproducibility of ONC's Inform HER-2/neu breast cancer test in the marketplace. The company said the agency will not require new clinical trials for its PMA, which was filed February 1994. ...